Children with congenital adrenal hyperplasia (CAH) — a rare adrenal disorder — routinely end up shorter than expected, and a new retrospective study may help explain why. Researchers tracked 63 pediatric patients over nearly three decades and found that near-final height averaged 1.20 standard deviations below population norms, with those in the more severe salt-wasting form faring slightly worse.

The study identified ages 6–10 as a potentially critical growth window, when bone age advancement accelerates and peaks. The typical adolescent growth spurt was blunted in both patient groups, and about a third showed early signs of puberty — though puberty timing alone didn't significantly affect final height. Higher hydrocortisone doses, both on average and during short-term increases, were associated with poorer height outcomes.

Key Takeaways:

• Near-final height was ~1.20 SD below population norms; corrected for parental height, it was -0.87 SD vs. a target of -0.33 SD
• Bone age advancement peaked around age 10, flagging ages 6–10 as a prime monitoring window
• Higher hydrocortisone doses correlated with lower height scores (P = .035 for average dose; P < .001 for short-term increases)
• Authors suggest this window may be optimal for intensified androgen suppression and potential use of aromatase inhibitors

Why it matters: For clinicians managing CAH in children, this study offers a clearer roadmap for when to act — and a caution against over-relying on higher steroid doses, which may inadvertently compromise growth.